Hodgkin Lymphoma Treatment at the University of Colorado Cancer Center
Nobody wants to hear the word “cancer” at the doctor’s office. But when you do, you need a team of experts you can trust.
At the University of Colorado Cancer Center, we specialize in Hodgkin lymphoma. We pull from the latest in lymphoma research to bring you the best in cutting-edge cancer treatment and care.
Your CU Cancer Center team of world-renowned specialists will tailor your treatment plan to your specific case. And this same expert team of doctors, nurses and specialists will stay with you throughout your entire journey.
Our dedication to a cure for cancer is unwavering. That’s why our 5-year survival rates are up to 30% higher than state, regional and national averages.
To begin your journey with your team of lymphoma experts, call us today at (720) 848-0300.
What is Hodgkin Lymphoma?
Lymphomas are a cancer of the immune system that results when a lymphocyte (which is a type of white blood cell that helps the body fight infections) undergoes a malignant change, and multiplies.
The malignant cells crowd out healthy cells, and may create tumors in the lymph nodes or other parts of the immune system.
Hodgkin lymphoma (formerly known as Hodgkin’s Disease) is named after Thomas Hodgkin, who first described these lymph node tumors in 1832.
About 40 years later, other types of lymphomas were identified, and grouped together as non-Hodgkin lymphoma.
Hodgkin Lymphoma at a Glance
- Approximately 153,535 people are living with Hodgkin Lymphoma or are in remission.
- An estimated 8,490 new cases of Hodgkin lymphoma are diagnosed in the United States each year.
- The five-year relative survival rate for patients with Hodgkin lymphoma has increased dramatically from 40 percent in caucasians from 1960-1963 to almost 88 percent for all races from 1999-2006.
Source: The Leukemia and Lymphoma Society